WASHINGTON, Dec 9 (Reuters) - The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the marketing of the epilepsy drug Neurontin.
WASHINGTON, Dec 9 (Reuters) - The U.S. Supreme Court said on Monday it would leave intact a $142 million jury verdict against Pfizer Inc over its marketing of the epilepsy drug Neurontin.
erode cash flows as these existing products face generic competition. Management recently settled with Wyeth (now part of Pfizer ) for $1.6 billion over Teva’s at-risk launch--before legal clearance--of generic Protonix launched in December
Tov : To enhance the safety and efficacy profile of its probable future blockbuster cancer drug, "Palbociclib," Pfizer ( PFE ) collaborated with GlaxoSmithKline ( GSK ) . The company will evaluate Palbociclib in combination with GlaxoSmithKline's
The Value Investor : Investors in Pfizer ( PFE ) were unpleasantly surprised after ..... While the bank remains upbeat about Pfizer 's prospects following the continued ..... at Goldman Sachs ( GS ) downgraded Pfizer from "Conviction Buy" to "Buy
NEW YORK, Dec 4 (Reuters) - Global drugmaker Pfizer Inc will broaden access to information from its scores of clinical trials to independent researchers and to patients who take part in the studies, the company said on Wednesday.
that much of the FDA's hesitance to approve Afrezza has to do with its predecessor in the inhaled insulin class. Pfizer 's PFE and Nektar's Exubera, the world's first inhaled insulin, was removed from the market in 2007 after the drug generated
Goldman removes Pfizer ( PFE ) from its Conviction Buy list. "We have long been advocates of the PFE breakup/ spin story [and although] we continue to expect PFE to move down the path of a full break
drug Xarelto generated $246 million in sales (JNJ's share) in the third quarter, while sales of Eliquis from Pfizer ( PFE ) and Bristol-Myers Squibb ( BMY ) were $41 million for the same period. The huge expectations that analysts had
The four remaining names that were on the list back then but are no longer represented were wide-moat rated Coke and Pfizer PFE ; narrow-moat rated ConocoPhillips COP; and, Burlington Northern Santa Fe (acquired by Berkshire Hathaway in late